About ADx NeuroSciences
ADx NeuroSciences is a Healthcare company based in Ghent (Belgium) founded in 2011. Biomarker assays for neurodegenerative diseases are developed using custom antibodies. ADx NeuroSciences has raised $3.17 million across 4 funding rounds from investors including European Union. The company has 14 employees. The company has since been acquired. ADx NeuroSciences offers products and services including Biomarker Assays and Tailor-made Antibodies. Its focus areas include Life Sciences, Neurology, In-Vitro Diagnostics and Neurodegenerative.
Company details
ADx NeuroSciences was founded in 2011 in Ghent, Belgium, within the biotechnology sector focused on neurodegenerative diseases. Biomarker assays are developed to detect indicators such as beta amyloid and tau in patient fluid samples, primarily cerebrospinal fluid, with emerging blood-based tests. Panels target Alzheimers disease, alongside Parkinsons disease, traumatic brain injury, and amyotrophic lateral sclerosis. Partnerships are maintained with Quanterix, Lilly, TauRx, and EuroImmun to support assay advancement.
- Headquarters Ghent, Belgium
- Employees 14
- Stage Acquired
- SectorsHealthcare
- Website adxneurosciences.com
- Social LinkedIn X
- Legal Name Adx Neurosciences
- Total Equity Funding$3.17M (USD)
in 4 rounds
- Latest Funding Round$588.08K (USD), Grant
Nov 2019
- Investors
- Employee Count14
Products & Services of ADx NeuroSciences
ADx NeuroSciences offers a comprehensive portfolio of products and services, including Biomarker Assays and Tailor-made Antibodies.
Assays for quantifying biomarkers in neurodegenerative diseases
Custom antibodies for detecting specific disease markers
Funding Insights of ADx NeuroSciences
ADx NeuroSciences has successfully raised a total of $3.17M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $588.08 thousand completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.17M
- Total Rounds 4
- Last Round Grant — $588,080
- First Round $1.84M
(Jul 2012)
- Investors Count 1
All 4 funding rounds of ADx NeuroSciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2019 | $588,080 | Grant | – | – | |
| Mar 2016 | Series B | – | – | – | |
| Aug 2013 | $1.33M | Series A | – | – | – |
| Jul 2012 | $1.84M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in ADx NeuroSciences
ADx NeuroSciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for ADx NeuroSciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ADx NeuroSciences
3 dated milestones of ADx NeuroSciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded ADx NeuroSciences is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Grant, of $588K.
Web traffic of ADx NeuroSciences
The website of ADx NeuroSciences (adxneurosciences.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 176.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adx Neurosciences
Complete news archive for ADx NeuroSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ADx NeuroSciences
ADx NeuroSciences was founded in 2011 and raised its 1st funding round 1 year after it was founded.
ADx NeuroSciences is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
ADx NeuroSciences is a funded company, having raised a total of $3.17M across 4 funding rounds to date. The company's 1st funding round was a Series A of $1.84M, raised on Jul 2012.
ADx NeuroSciences has 14 employees.
ADx NeuroSciences was founded in 2011 in Ghent, Belgium, within the biotechnology sector focused on neurodegenerative diseases. Biomarker assays are developed to detect indicators such as beta amyloid and tau in patient fluid samples, primarily cerebrospinal fluid, with emerging blood-based tests. Panels target Alzheimers disease, alongside Parkinsons disease, traumatic brain injury, and amyotrophic lateral sclerosis. Partnerships are maintained with Quanterix, Lilly, TauRx, and EuroImmun to support assay advancement.
ADx NeuroSciences offers Biomarker Assays and Tailor-made Antibodies.
ADx NeuroSciences has 1 investor. Key investors include European Union.
ADx NeuroSciences operates through Adx Neurosciences.